# Cencora, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Cencora, Inc.). ## Overview Cencora is a pharmaceutical sourcing and distribution company that sits between drug manufacturers and healthcare providers, moving branded, specialty, generic, and over-the-counter products through a large distribution network. It also sells higher-value services around commercialization, regulatory support, logistics, inventory management, and pharmacy operations. The company serves hospitals, pharmacies, clinics, veterinarians, and other care settings in the United States and selected international markets. Its business model is built on high-volume distribution plus service add-ons that help customers improve access, efficiency, and patient care. ## Products & services • Pharmaceutical distribution for brand, specialty, generic and OTC products • Home healthcare supplies and equipment • Specialty transportation and premium logistics services • Regulatory, market access and pharmacovigilance services • Inventory management, pharmacy automation and packaging solutions • Reimbursement and pharmaceutical consulting services - **U.S. Healthcare Solutions distribution** (85%) — Wholesale distribution of pharmaceuticals and healthcare products to U.S. provider and pharmacy customers. - **International Healthcare Solutions** (9%) — Pharmaceutical wholesale and related services in Europe, Canada and other select markets. - **Global commercialization services** (3%) — Regulatory, market access, development consulting, pharmacovigilance and quality services for life sciences clients. - **Specialty logistics and supply chain services** (2%) — Premium logistics, cold-chain and specialty transportation services for biopharma and healthcare customers. - **Animal health distribution** (1%) — Veterinary pharmaceutical and related product distribution through animal health channels. - Pharmaceutical distribution of brand-name, specialty and generic drugs - Over-the-counter healthcare products and related sundries - Home healthcare supplies and equipment - Specialty transportation and premium logistics for biopharma - Regulatory affairs, market access and pharmacovigilance services - Inventory management, pharmacy automation and packaging solutions - Reimbursement and pharmaceutical consulting services ## Customers Cencora sells primarily to healthcare providers that need reliable, high-frequency access to medicines and related supplies, including retail pharmacies, health systems, hospitals, clinics, long-term care facilities, dialysis centers, physicians and veterinarians. It also serves pharmaceutical and biotech manufacturers that need distribution reach, commercialization support, and specialized logistics to launch and move products through the channel. In the U.S., many customers rely on Cencora as a primary supplier, which makes service levels, credit terms, and product availability central to retention. Internationally, the customer base is more mixed, with European wholesale customers and life sciences clients using the company for both distribution and specialized support services. - **U.S. retail and specialty pharmacies** (primary) — Buy branded, generic and specialty pharmaceuticals for daily dispensing and patient access. - **Hospitals and health systems** (primary) — Source pharmaceuticals, specialty therapies and supply-chain services to support inpatient and outpatient care. - **Physician practices and clinics** (primary) — Purchase specialty and office-administered drugs, especially for oncology, chronic care and infusion-related use. - **Pharmaceutical and biotech manufacturers** (secondary) — Buy logistics, regulatory, market access and commercialization services to support product launches and lifecycle management. - **International wholesale and healthcare customers** (secondary) — Purchase pharmaceuticals and related services in Europe, Canada and other select markets. - **Veterinary and animal health customers** (secondary) — Buy veterinary pharmaceuticals and related products through the animal health distribution business. - Independent and chain retail pharmacies buying broad drug assortments and replenishment - Hospitals and health systems sourcing pharmaceuticals and specialty products - Physician practices, medical clinics and dialysis centers needing regular supply - Long-term care and alternate site pharmacies requiring dependable distribution - Veterinarians and animal health customers buying veterinary pharmaceuticals - Pharmaceutical and biotech manufacturers buying logistics and commercialization support ## Geography Cencora is anchored in the United States, where most of its revenue is generated through the U.S. Healthcare Solutions segment and where its distribution network is most extensive. The company also operates in select global markets, with International Healthcare Solutions focused on Europe and Canada and additional exposure to other non-U.S. markets. Management disclosed that revenue from foreign operations was approximately 9% of consolidated revenue in fiscal 2025, which indicates that international business is meaningful but still secondary to the U.S. base. The company’s foreign currency exposure is concentrated in the U.K. pound sterling, euro, Turkish lira, Brazilian real and Canadian dollar, showing that international operations create both translation and transaction risk. - **United States** (91%) — Estimated from disclosure that foreign operations were approximately 9% of consolidated revenue in fiscal 2025. - **International** (9%) — Estimated from disclosure of foreign operations revenue share and international market presence. - United States is the core market and the main source of revenue - Europe is a key international distribution and commercialization market - Canada is an important international healthcare solutions market - Foreign operations contributed about 9% of fiscal 2025 revenue - Currency exposure includes GBP, EUR, TRY, BRL and CAD - Distribution network and service centers support both U.S. and international customers ## Strategy Cencora’s strategy is to strengthen execution in its core distribution business while expanding higher-margin adjacencies that support manufacturers and providers. The company is investing in distribution network expansion, technology initiatives and service capabilities that improve efficiency, reliability and customer stickiness. It is also using acquisitions, such as RCA, to add scale and broaden capabilities in areas that can support growth and operating leverage. The strategic logic is to combine low-margin but essential distribution with services that deepen relationships and improve economics over time. - **Expand and enhance the distribution network** (short-term) — Capacity, service reliability and speed are critical in pharmaceutical distribution and support customer retention. - **Invest in technology and automation** (medium-term) — Technology improves inventory control, pharmacy operations and operating efficiency across a high-volume supply chain. - **Grow higher-margin manufacturer services** (medium-term) — Commercialization and consulting services can improve mix and reduce reliance on pure distribution economics. - **Pursue disciplined acquisitions** (medium-term) — Acquisitions can add scale, customer relationships and specialized capabilities, but must be integrated carefully. - Improve execution in core U.S. and international distribution - Expand higher-margin services for pharmaceutical manufacturers - Invest in distribution network capacity and technology - Use acquisitions to add scale and service capabilities - Support specialty and GLP-1-related demand growth - Increase operating leverage through network efficiency ## Risks Cencora’s business is exposed to customer concentration and contract renewal risk because a loss of a key customer or group purchasing organization can quickly affect revenue and cash flow. The company also depends on a complex supply chain and third-party partners, so cyber incidents at suppliers, subcontractors or logistics partners could disrupt distribution and service delivery. Regulatory, legal and reputational risks are elevated in pharmaceutical distribution because the company operates in a heavily scrutinized channel and has faced opioid-related litigation and tax uncertainty. More generally, margin pressure, pricing competition, product mix shifts and foreign exchange volatility can affect results because the business combines low-margin distribution with service businesses that must scale efficiently. - **Key customer or GPO loss** [high] — Revenue and cash flow can fall quickly if a major customer leaves or renews on less favorable terms. - **Third-party cybersecurity incident** [high] — The company relies on suppliers, subcontractors and logistics partners to move products and provide services. - **Opioid-related litigation and legal accruals** [high] — Historical prescription opioid distribution litigation can create large cash and earnings volatility. - **Foreign exchange and inflation in non-U.S. markets** [medium] — International operations expose earnings to currency swings and, in Turkey, highly inflationary accounting. - **Goodwill and intangible asset impairment** [medium] — Acquisitions and trade names create balance-sheet assets that can be written down if performance weakens. - Loss or repricing of key customers or group purchasing organizations - Cybersecurity incidents at suppliers, subcontractors or logistics partners - Regulatory, legal and reputational exposure in pharmaceutical distribution - Opioid-related litigation and related contingent liabilities - Foreign exchange volatility from non-U.S. operations - Margin pressure from competition, pricing and product mix changes ## Accounting Cencora’s reported results are affected by several judgment-heavy accounting areas that investors should watch closely. Goodwill and intangible asset impairment is important because the company has recorded sizable charges, including goodwill impairment, and acquisitions create large intangible balances that can be written down if growth or margins weaken. Revenue and cash flow can be seasonal and working-capital intensive, since operating cash flow varies with period-end balances, customer payment terms and supplier terms in a distribution model. The company also uses foreign currency hedges and has exposure to highly inflationary accounting in Turkey, which can affect cost of goods sold and reported earnings. In addition, allowances for returns and credit losses, uncertain tax positions, and litigation-related accruals can materially change reported profitability and balance-sheet liabilities. - **Goodwill and intangible asset impairment** — Can materially reduce operating income and net income - **Working capital and cash flow timing** — Affects operating cash flow and liquidity analysis - **Foreign currency and highly inflationary accounting** — Affects gross margin and operating results - **Allowances for returns and credit losses** — Affects revenue netting and bad debt expense - **Litigation and uncertain tax positions** — Affects provisions, liabilities and cash outflows - Goodwill and intangible asset impairment can create large non-cash charges - Acquisition accounting affects goodwill, intangibles and amortization - Working capital swings can cause significant quarter-to-quarter cash flow volatility - Foreign currency hedging and translation affect non-U.S. results - Highly inflationary accounting in Turkey affects cost of goods sold - Returns, credit losses, tax positions and litigation accruals require estimates --- *Last updated: 2026-08-11T04:03:56.228997+00:00*